Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute ’s early Detection Research Network
Hepatocellular carcinoma (HCC) is a common malignancy with a steadily rising incidence and associated morbidity and mortality. Cirrhosis of the liver is presently the leading risk factor for developing HCC. Abdominal imaging, with or without alpha-fetoprotein (AFP) testing, every 6 months is the current surveillance strategy for patients at risk. The available biomarkers for detecting this cancer at an early stage have inadequate sensitivity and specificity.
Source: Contemporary Clinical Trials - Category: Radiology Authors: Kelly A. Borges, Jianliang Dai, Neehar D. Parikh, Myron Schwartz, Mindie H. Nguyen, Lewis R. Roberts, Alex S. Befeler, Sudhir Srivastava, Jo Ann Rinaudo, Ziding Feng, Jorge A. Marrero, K. Rajender Reddy Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cirrhosis | Clinical Trials | Hepatocellular Carcinoma | Liver | Liver Cancer | Radiology | Study | Urology & Nephrology